Moleculin Biotech, Inc. (NASDAQ:MBRX – Get Free Report) was the target of a large drop in short interest during the month of October. As of October 30th, there was short interest totaling 54,541 shares, a drop of 56.8% from the October 15th total of 126,324 shares. Based on an average trading volume of 67,646 shares, the days-to-cover ratio is presently 0.8 days. Currently, 6.5% of the company’s shares are sold short.
Analyst Ratings Changes
A number of equities research analysts have issued reports on the stock. Wall Street Zen lowered shares of Moleculin Biotech from a “sell” rating to a “strong sell” rating in a report on Saturday, November 7th. HC Wainwright lowered their price objective on Moleculin Biotech to $60.00 and set a “buy” rating for the company in a research report on Friday, August 28th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a research report on Thursday, October 15th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Moleculin Biotech currently has an average rating of “Hold” and a consensus price target of $60.00.
View Our Latest Analysis on MBRX
Moleculin Biotech Trading Down 2.4%
Shares of Moleculin Biotech stock traded down $0.19 during trading hours on Friday, reaching $7.87. 9,899 shares of the stock traded hands, compared to its average volume of 43,939. The company has a 50 day moving average price of $9.94 and a 200 day moving average price of $36.71. Moleculin Biotech has a one year low of $3.23 and a one year high of $229.40.
Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last announced its earnings results on Friday, November 13th. The company reported ($9.59) EPS for the quarter, missing analysts’ consensus estimates of ($8.87) by ($0.72). Analysts predict that Moleculin Biotech will post -47.40 EPS for the current year.
Moleculin Biotech Company Profile
Moleculin Biotech is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing treatments for cancer and other serious diseases. Its research centers on drug candidates intended to address cancers that can be difficult to treat with existing therapies. The company’s pipeline includes Annamycin, an investigational anthracycline being studied for acute myeloid leukemia and soft-tissue sarcoma that has spread to the lungs. Moleculin has described Annamycin as designed to avoid some limitations associated with older anthracyclines, including heart-related toxicity.
Further Reading
- Five stocks we like better than Moleculin Biotech
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
